|Bid||45.53 x 800|
|Ask||47.39 x 1400|
|Day's range||46.27 - 46.63|
|52-week range||40.38 - 51.18|
|Beta (5Y monthly)||0.38|
|PE ratio (TTM)||29.79|
|Earnings date||25 Jul 2023 - 31 Jul 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||53.98|
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QIAGEN is a one-stop shop for all research needs, including solutions for sample preparation, automation and bioinformatics with enzyme offering expansion.
QIAGEN (QGEN) is likely to benefit from high organic growth across its non-COVID-19 product group and portfolio advancements, reflecting a positive share price movement.
Amid an uncertain macroeconomic environment, Qiagen's (QGEN) first-quarter results reflect an impressive organic top line, led by strength in non-COVID-19 product groups.
Qiagen (QGEN) delivered earnings and revenue surprises of 8.51% and 0.09%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Q1 2023: Net sales of $485 million (-23% at actual rates, -20% at constant exchange rates, CER); diluted EPS of $0.37 and adjusted diluted EPS of $0.51 // Net sales at CER of $502 million ahead of outlook for at least $490 million CER and adjusted diluted EPS of $0.52 CER ahead of outlook for at least $0.47 CER // 12% CER sales growth in non-COVID product portfolio to $434 million, while COVID product sales decline 76% to $52 million // Full-year 2023 outlook reaffirmed for at least $2.05 billio
Venlo, the Netherlands, and Germantown, Maryland, May 03, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it welcomed the U.S. Preventive Services Task Force (USPSTF) reaffirming a previously issued recommendation for latent tuberculosis infection (LTBI) screening by primary care physicians in populations at increased risk. The USPSTF issued a final report on May 2 to continue the “B” recommendation for screening of these populations, building on
Qiagen (QGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
It is hard to get excited after looking at Qiagen's (NYSE:QGEN) recent performance, when its stock has declined 10...
Japan to become the latest of more than 100 countries where QIAstat-Dx is available for molecular testing in diagnosing over 20 respiratory diseases from one patient sample // Generates actionable results in about one hour based on PCR technology, unique ability to provide Ct values and easy access to amplification curves to support clinical decisions // More than 3,500 QIAstat-Dx instruments installed worldwide at the end of 2022Venlo, the Netherlands, April 24, 2023 (GLOBE NEWSWIRE) -- QIAGEN
Steve Rusckowski has joined Supervisory Board and will stand for election at Annual General Meeting in June 2023Venlo, the Netherlands, April 20, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Steve Rusckowski, an internationally recognized healthcare industry executive and former Chairman, President and CEO of Quest Diagnostics, has joined the Supervisory Board as a new member and will stand for election at the next Annual General Meeting schedu
Solid Biosciences Inc. (SLDB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Launch of cell-free DNA (cfDNA) next-generation sequencing kits to test liquid biopsies // Study to demonstrate QIAGEN’s expertise in detecting disease-relevant cfDNA mutations // New pan-cancer panels for digital PCR platform QIAcuity to be launched in fall 2023Venlo, the Netherlands, April 14, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAseq Targeted cfDNA Ultra Panels that will enable researchers studying cancer and other disease
In terms of QIAstat-Dx, QIAGEN (QGEN) continues to witness increased demand for system placements and growing consumables usage around the world.
QIAGEN (QGEN) QIAxcel Connect automates the analysis of the size and quality of isolated DNA and RNA.
International design competition recognizes high-resolution DNA or RNA capillary electrophoresis instrument // QIAxcel marks the fourth QIAGEN instrument to receive Red Dot award, highlights strategy of upgrading portfolio to add new features – in particular wireless connectivity // QIAxcel Connect offers scientists many benefits for nucleic acid analysis with minimal handling time, flexible throughput and speedVenlo, the Netherlands, March 29, 2023 (GLOBE NEWSWIRE) -- QIAGEN today announced tha
Key Insights Significantly high institutional ownership implies Qiagen's stock price is sensitive to their trading...
Tango Therapeutics, Inc. (TNGX) delivered earnings and revenue surprises of 8.33% and 2.86%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
SBTi has validated the QIAGEN targets to reach net-zero greenhouse gas (GHG) emissionsVenlo, The Netherlands, March 27, 2023 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its emissions reduction targets have been validated by the Science Based Targets initiative (SBTi) – a global recognition of its ambitions to honor the Paris Agreement’s climate goals. The SBTi is a global body that enables companies to set ambitious emissions reductions target
VENLO, The Netherlands, March 13, 2023--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2022, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN’s website here.
QIAGEN (QGEN) will develop a real-time in vitro PCR test that can be utilized to spot IDH1 gene mutations in AML patients in whole blood and bone marrow aspirates.
VENLO, the Netherlands, March 09, 2023--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has entered into a strategic partnership with Servier, a global pharmaceutical group, to develop a companion diagnostic test for TIBSOVO®, an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of the blood cancer acute myeloid leukemia (AML).
Recent developments in the Molecular Diagnostics space have been aiding key MedTech players like BD (BDX) to boost their business.
VENLO, Netherlands, March 01, 2023--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the new QIAseq Platform Partnership program and the first partnership with medical data-analysis provider SOPHiA GENETICSTM (Nasdaq: SOPH) that will bring together its QIAseq reagent technology for next-generation sequencing (NGS) with the SOPHiA DDMTM digital analytics platform.